Predictors of Anti-Drug Antibodies and Drug Discontinuation Among Pediatric Patients with Inflammatory Bowel Disease in a Large Learning Health System

Purpose: The purpose of this study is to evaluate the trends in biologic drug discontinuation, reasons for discontinuation, and evaluation performed prior to discontinuation in patients enrolled in the ImproveCareNow network.

Specific Aims:

1. Determine the frequency of biologic drug discontinuation, including associations with patient and practice characteristics, as well as drug dosing and monitoring.
2. Determine the associations between biologic drug discontinuation and adverse events, evaluation performed prior to drug discontinuation, and barriers to care.
3. Develop materials and quality improvement processes aimed at reducing biologic drug discontinuation.
4. BISCUIT - The Biologic dISContinUatIon sTudy - Disease Outcomes. Funded by The Gary and Rachel Glick Charitable Fund.

Study Period: January 2021-December 2022

Contact: Jeremy Adler